Raymond James & Associates Apellis Pharmaceuticals, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 48,010 shares of APLS stock, worth $976,043. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,010
Previous 29,582 62.29%
Holding current value
$976,043
Previous $1.13 Million 22.05%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$28.84 - $41.15 $531,463 - $758,312
18,428 Added 62.29%
48,010 $1.38 Million
Q2 2024

Jul 19, 2024
BUY
$38.07 - $59.71 $404,569 - $634,538
10,627 Added 56.06%
29,582 $1.13 Million
Q1 2024

Apr 22, 2024
BUY
$55.39 - $72.47 $197,631 - $258,572
3,568 Added 23.19%
18,955 $1.11 Million
Q4 2023

Jan 16, 2024
SELL
$37.14 - $64.82 $989,149 - $1.73 Million
-26,633 Reduced 63.38%
15,387 $921,000
Q3 2023

Oct 24, 2023
SELL
$23.65 - $89.22 $83,484 - $314,946
-3,530 Reduced 7.75%
42,020 $1.6 Million
Q2 2023

Jul 25, 2023
SELL
$76.68 - $93.31 $1.23 Million - $1.49 Million
-15,978 Reduced 25.97%
45,550 $4.15 Million
Q1 2023

Apr 14, 2023
BUY
$46.59 - $66.96 $2.19 Million - $3.15 Million
47,091 Added 326.18%
61,528 $4.06 Million
Q4 2022

Feb 08, 2023
BUY
$43.24 - $61.04 $17,512 - $24,721
405 Added 2.89%
14,437 $746,000
Q3 2022

Oct 25, 2022
BUY
$44.76 - $69.66 $267,799 - $416,775
5,983 Added 74.33%
14,032 $958,000
Q2 2022

Aug 12, 2022
BUY
$35.07 - $59.21 $58,356 - $98,525
1,664 Added 26.06%
8,049 $364,000
Q1 2022

May 11, 2022
SELL
$35.46 - $54.12 $16,134 - $24,624
-455 Reduced 6.65%
6,385 $324,000
Q4 2021

Feb 08, 2022
SELL
$30.74 - $49.16 $12,787 - $20,450
-416 Reduced 5.73%
6,840 $323,000
Q3 2021

Nov 02, 2021
SELL
$31.4 - $69.84 $8,289 - $18,437
-264 Reduced 3.51%
7,256 $239,000
Q2 2021

Aug 11, 2021
SELL
$40.9 - $64.9 $327,118 - $519,070
-7,998 Reduced 51.54%
7,520 $475,000
Q1 2021

May 14, 2021
BUY
$40.8 - $57.39 $381,072 - $536,022
9,340 Added 151.18%
15,518 $666,000
Q4 2020

Feb 12, 2021
BUY
$30.79 - $57.2 $190,220 - $353,381
6,178 New
6,178 $353,000
Q3 2020

Nov 04, 2020
SELL
$25.89 - $33.65 $166,265 - $216,100
-6,422 Closed
0 $0
Q2 2020

Jul 28, 2020
SELL
$24.8 - $38.49 $43,474 - $67,472
-1,753 Reduced 21.44%
6,422 $210,000
Q1 2020

Apr 21, 2020
BUY
$17.91 - $44.33 $146,414 - $362,397
8,175 New
8,175 $219,000

Others Institutions Holding APLS

# of Institutions
329
Shares Held
123M
Call Options Held
4.12M
Put Options Held
756K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.23B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email